Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)3.67
  • Today's Change0.26 / 7.62%
  • Shares traded21.27k
  • 1 Year change-13.34%
  • Beta0.6983
Data delayed at least 15 minutes, as of Feb 16 2026 13:32 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

  • Revenue in CHF (TTM)0.00
  • Net income in CHF-60.24m
  • Incorporated2004
  • Employees153.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Abionyx Pharma SA3.94m-4.19m115.99m51.00--22.66--29.43-0.1317-0.13170.12380.15820.303317.397.1684,823.53-32.25-26.53-43.11-38.3117.7815.59-106.31-131.061.35--0.4281---1.92---24.53------
Xlife Sciences AG839.38k30.75m118.24m17.005.030.38792.87140.864.084.080.128452.840.0016--0.090749,375.294.806.015.957.3762.1737.442,991.342,987.921.07--0.131---15.5410.15130.37100.79-13.48--
Nightingale Health Oyj4.28m-16.82m124.15m100.00--1.53--29.04-0.3052-0.30520.07781.100.05680.94442.7946,930.00-22.33-15.66-24.26-16.9575.3975.21-393.39-447.178.52--0.0511--7.6921.38-5.71---12.69--
Innate Pharma SA5.47m-41.96m125.38m181.00--26.30--22.94-0.5497-0.54970.07140.05580.0491--15.8133,149.17-37.68-13.19-52.10-17.1749.5291.15-767.52-88.46----0.8401---75.68-28.80-553.51---64.08--
Ryvu Therapeutics SA15.10m-25.68m125.80m294.00--8.16--8.33-5.13-5.133.023.080.21212.297.31237,411.60-36.05-23.64-48.51-27.8470.8629.35-170.05-208.852.26--0.572--66.3883.01-20.98---24.46--
Solar Foods Oyj17.41k-9.72m127.96m57.00--6.61--7,349.74-0.433-0.4330.00080.71150.0004--0.0037455.00-22.45---27.05--25,931.57---55,808.37-----7.030.5092--275.15---22.57------
Heidelberg Pharma AG2.77m-23.85m129.58m114.00--13.51--46.82-0.558-0.5580.06470.22510.05070.032969.1428,928.10-43.69-40.90-50.29-58.5184.6655.95-861.83-228.643.55--0.7766---30.53-1.294.74---13.09--
Maat Pharma SA3.57m-28.36m133.43m60.00--15.13--37.34-2.15-2.150.2700.51410.078611.220.578565,366.67-62.39-41.51-90.20-51.8761.68---793.83-976.992.21-29.530.6346--44.34---46.59--42.53--
Intellego Technologies AB66.32m25.35m133.59m65.004.752.334.812.019.819.8125.9120.011.2810.592.3212,432,400.0049.1117.1361.6423.8770.9758.8238.2321.324.115.350.0617--42.25222.7114.78------
BioVersys AG-100.00bn-100.00bn135.67m-------------------------------------------------------2.28------
Molecular Partners AG0.00-60.24m137.68m153.00--1.34-----1.63-1.630.002.550.00----0.00-45.23-13.09-49.34-15.66--99.25---56.51----0.0158---29.38-24.5912.81---17.26--
Thor Medical ASA8.08k-4.76m146.22m13.00--3.77--18,093.33-0.223-0.2230.00041.360.0002--0.007811,111.11-13.37-59.74-13.90-81.16-----58,908.00--8.78--0.018-------659.00---33.37--
BioInvent International AB21.07m-27.87m146.91m124.00--2.50--6.97-4.91-4.913.7210.380.2614--4.902,147,790.00-34.58-19.38-38.20-20.57-----132.30-189.977.31--0.0154---37.47-13.77-29.99--21.19--
Devyser Diagnostics AB20.89m-2.17m147.00m115.00--5.011,220.487.04-1.52-1.5214.6620.480.52621.405.531,839,394.00-5.64-10.61-6.60-12.0481.9680.33-10.71-28.672.27-2.030.1312--28.1227.53-14.74--52.54--
Scancell Holdings Plc4.94m-5.77m152.23m60.00------30.84-0.0053-0.00530.0047-0.00810.2946--8.2678,516.66-34.46-33.29---44.2394.95---116.98-502.03----2.07-------109.46--124.48--
Sensorion SA0.00-25.59m158.58m68.00--1.78-----0.0931-0.09310.000.18950.00----0.00-32.12-34.53-38.36-43.50------------0.0265-------17.72--98.90--
Data as of Feb 16 2026. Currency figures normalised to Molecular Partners AG's reporting currency: Swiss Franc CHF

Institutional shareholders

30.77%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 25 Oct 20248.53m21.14%
UBS Asset Management Switzerland AGas of 19 Dec 20252.05m5.09%
GAM Investment Management (Switzerland) AGas of 31 Mar 2025989.70k2.45%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 2025334.24k0.83%
Pictet Asset Management SAas of 31 Oct 2025143.94k0.36%
Zenito Oyas of 30 Dec 2025123.95k0.31%
BlackRock Asset Management Deutschland AGas of 05 Feb 202697.15k0.24%
LLB Asset Management AGas of 31 Dec 202563.01k0.16%
Migros Bank AGas of 30 Jun 202546.33k0.12%
Swiss Life Asset Management AGas of 30 Sep 202536.84k0.09%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.